Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024 08:00 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 07, 2024 08:00 ET
|
Phathom Pharmaceuticals
Launched VOQUEZNA® (vonoprazan) tablets in November 2023 for the treatment of Erosive GERD (gastroesophageal reflux disease), achieving net revenues of $0.7 million for the fourth quarter Early...
Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board
February 21, 2024 08:19 ET
|
Biomerica, Inc.
IRVINE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, proudly announces the...
Diagnostics Industry Leader Jack Kenny Appointed as Chairman of the Board at Biomerica
January 23, 2024 08:19 ET
|
Biomerica, Inc.
Mr. Kenny has significant executive experience and a proven track record in medical diagnostics and healthcare Mr. Kenny most recently served as CEO of Meridian Bioscience where he successfully built...
Biomerica Reports Second Quarter 2024 Financial Results
January 16, 2024 08:19 ET
|
Biomerica, Inc.
Revenues excluding Covid test sales increased 10.3% for the second fiscal quarter of 2024 vs the second fiscal quarter of 2023.Loss per shares narrows to $0.09 per share from $0.12 per share...
Biomerica Received US FDA 510(k) Clearance for Their Hp Detect™ ELISA Test Product Designed to Detect the Presence of the H. pylori Bacteria That infects Approximately 35% of the U.S. Population
December 18, 2023 07:47 ET
|
Biomerica, Inc.
Over 80% of gastric cancers are attributed to H. pylori bacterial infection Gastric cancer is the third most common cause of cancer related death in the world ...
Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
October 30, 2023 08:00 ET
|
Phathom Pharmaceuticals
Planning for a December 2023 U.S. launch for H. pylori, together with the U.S. launch of vonoprazan for Erosive GERD, if approved FLORHAM PARK, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Phathom...
Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA
May 23, 2023 16:00 ET
|
Phathom Pharmaceuticals
Anticipated FDA action date in Q4 2023; if approved, combined launch for Erosive GERD and H. pylori indications planned before year endIf approved, vonoprazan would be the first innovative acid...
Phathom Pharmaceuticals Reports First Quarter 2023 Results
May 10, 2023 08:00 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023
May 09, 2023 08:00 ET
|
Phathom Pharmaceuticals
Higher H. pylori eradication rates demonstrated with vonoprazan-based regimens vs. lansoprazole triple therapy, regardless of different baseline demographics and clinical characteristicsMeta-analysis...